C-terminal HGH fragment that mimics GH's fat-burning effects without growth-promoting activity.
Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat creation) via the beta-3 adrenergic receptor. Specifically targets adipose tissue without the anabolic or blood sugar effects of full growth hormone.
FDA GRAS (Generally Recognized as Safe) status for use in food. Developed by Metabolic Pharmaceuticals. Has been tested in clinical trials for obesity at doses up to 1mg/day with good safety profile.
Does not affect IGF-1 levels or produce growth-related effects. This makes it theoretically suitable for fat loss research without the concerns associated with full HGH, including potential proliferative effects.